Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Nat-Escitalopram (02440296), Nat-Escitalopram (02440318). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
ESCITALOPRAM
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable
- Citalopram (Celexa): general benefit, Not a benefit
- Fluoxetine (Prozac): general benefit, Not a benefit
- Fluvoxamine (Luvox): general benefit
- Paroxetine (Paxil): general benefit, Not a benefit
- Sertraline (Zoloft): general benefit
- Amitriptyline (Elavil): general benefit
17 more in the class list below
Act Escitalopram ODT · DIN 02454297 · 10mg · Orally Disintegrating tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Escitalopram ODT · DIN 02454297
Manufacturer: Actavis Pharma Company; listing date 2016-11-30
Health Canada: Marketed since 2020-05-01 · brand ACT ESCITALOPRAM ODT · ATC N06AB10 ESCITALOPRAM · form Tablet (orally-disintegrating) · route Oral · ingredients ESCITALOPRAM 10 MG · company Teva canada limited · schedule Prescription
Act Escitalopram ODT: Formulary list price $1.3199/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3199 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94081 · Verify on the e-Formulary ↗ (DIN 02454297)
Source record
DIN 02454297: Act Escitalopram ODT
Raw flags: sec3=Y
Item: 281604127; group id 460; item number 1150; lccId None; manufacturer id ACV
Source form: Orally Disintegrating Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.3199; ministry $1.3199
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454297
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94081
Interchangeable products
Cipralex MELTZ · DIN 02391449 · not recorded
Shortage status: resolved shortage (ended 2025-12-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454297
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Escitalopram · DIN 02434652 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Escitalopram · DIN 02434652
Manufacturer: Accord Healthcare Inc.; listing date 2017-12-21
Health Canada: Marketed since 2016-06-10 · brand ACH-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Accord healthcare inc · schedule Prescription
Ach-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91896 · Verify on the e-Formulary ↗ (DIN 02434652)
Source record
DIN 02434652: Ach-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02434652
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91896
Interchangeable products
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: active shortage (reported not recorded, estimated to end 2026-09-30, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02434652
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Escitalopram · DIN 02295016 · 10mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Escitalopram · DIN 02295016
Manufacturer: Apotex Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-10 · brand APO-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Apotex inc · schedule Prescription
Apo-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78034 · Verify on the e-Formulary ↗ (DIN 02295016)
Source record
DIN 02295016: Apo-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295016
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78034
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2024-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295016
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Escitalopram · DIN 02397358 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Escitalopram · DIN 02397358
Manufacturer: Auro Pharma Inc.; listing date 2014-12-18
Health Canada: Marketed since 2014-09-10 · brand AURO-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Auro pharma inc · schedule Prescription
Auro-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88231 · Verify on the e-Formulary ↗ (DIN 02397358)
Source record
DIN 02397358: Auro-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397358
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88231
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2024-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397358
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cipralex · DIN 02263238 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Cipralex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Cipralex · DIN 02263238
Manufacturer: Lundbeck Canada Inc.; listing date 2008-11-04
Health Canada: Marketed since 2005-02-14 · brand CIPRALEX -10MG · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Lundbeck canada inc · schedule Prescription
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74862 · Verify on the e-Formulary ↗ (DIN 02263238)
Source record
DIN 02263238: Cipralex
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id VLH
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $2.3825; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02263238
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74862
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02263238
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Escitalopram · DIN 02429039 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Escitalopram · DIN 02429039
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2018-11-01 · brand ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91347 · Verify on the e-Formulary ↗ (DIN 02429039)
Source record
DIN 02429039: Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429039
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91347
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2020-03-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429039
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Escitalopram · DIN 02430118 · 10mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Escitalopram · DIN 02430118
Manufacturer: Sanis Health Inc.; listing date 2016-09-29
Health Canada: Marketed since 2014-09-18 · brand ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Sanis health inc · schedule Prescription
Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91451 · Verify on the e-Formulary ↗ (DIN 02430118)
Source record
DIN 02430118: Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02430118
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91451
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: anticipated shortage (last updated 2026-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02430118
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Escitalopram · DIN 02508893 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Escitalopram · DIN 02508893
Manufacturer: Jamp Pharma Corporation; listing date 2024-02-29
Health Canada: Marketed since 2023-12-22 · brand JAMP ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99822 · Verify on the e-Formulary ↗ (DIN 02508893)
Source record
DIN 02508893: Jamp Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508893
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99822
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508893
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Escitalopram · DIN 02429780 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Escitalopram · DIN 02429780
Manufacturer: Jamp Pharma Corporation; listing date 2014-11-27
Health Canada: Marketed since 2023-04-26 · brand ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91422 · Verify on the e-Formulary ↗ (DIN 02429780)
Source record
DIN 02429780: Jamp-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429780
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91422
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429780
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Escitalopram · DIN 02471418 · 10mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Escitalopram · DIN 02471418
Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2026-03-23 · brand M-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Mantra pharma inc · schedule Prescription
M-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96051 · Verify on the e-Formulary ↗ (DIN 02471418)
Source record
DIN 02471418: M-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id MAT
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471418
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96051
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2024-05-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471418
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Escitalopram · DIN 02423480 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Escitalopram · DIN 02423480
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-10 · brand MAR-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90820 · Verify on the e-Formulary ↗ (DIN 02423480)
Source record
DIN 02423480: Mar-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423480
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90820
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2020-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423480
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Escitalopram · DIN 02407418 · 10mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Escitalopram · DIN 02407418
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2016-02-25
Health Canada: Marketed since 2015-03-19 · brand MINT-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89210 · Verify on the e-Formulary ↗ (DIN 02407418)
Source record
DIN 02407418: Mint-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id MIN
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407418
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89210
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2020-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02407418
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Escitalopram · DIN 02309467 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mylan-Escitalopram · DIN 02309467
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2014-11-27
Health Canada: Marketed since 2014-09-10 · brand MYLAN-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79506 · Verify on the e-Formulary ↗ (DIN 02309467)
Source record
DIN 02309467: Mylan-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id MYL
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309467
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79506
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2024-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02309467
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Escitalopram · DIN 02476851 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Escitalopram · DIN 02476851
Manufacturer: Nora Pharma; listing date 2020-06-30
Health Canada: Marketed since 2024-03-08 · brand NRA-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Nora pharma inc · schedule Prescription
NRA-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96678 · Verify on the e-Formulary ↗ (DIN 02476851)
Source record
DIN 02476851: NRA-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id NRA
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476851
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96678
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02476851
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Natco-Escitalopram · DIN 02554909 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Natco-Escitalopram · DIN 02554909
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2025-11-28
Health Canada: Marketed since 2025-08-29 · brand NATCO-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Natco pharma (canada) inc · schedule Prescription
Natco-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104373 · Verify on the e-Formulary ↗ (DIN 02554909)
Source record
DIN 02554909: Natco-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id NAT
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554909
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104373
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554909
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Escitalopram · DIN 02469243 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Escitalopram · DIN 02469243
Manufacturer: Pharmascience Inc.; listing date 2018-09-27
Health Canada: Marketed since 2021-08-10 · brand PMS-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Pharmascience inc · schedule Prescription
PMS-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95793 · Verify on the e-Formulary ↗ (DIN 02469243)
Source record
DIN 02469243: PMS-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469243
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95793
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2021-10-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469243
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Escitalopram · DIN 02385481 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Escitalopram · DIN 02385481
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2014-11-27
Health Canada: Marketed since 2026-03-13 · brand SPC-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Sun pharma canada inc · schedule Prescription
Ran-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87111 · Verify on the e-Formulary ↗ (DIN 02385481)
Source record
DIN 02385481: Ran-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385481
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87111
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2025-03-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385481
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Escitalopram · DIN 02364077 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Escitalopram · DIN 02364077
Manufacturer: Sandoz Canada Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-10 · brand SANDOZ ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84901 · Verify on the e-Formulary ↗ (DIN 02364077)
Source record
DIN 02364077: Sandoz Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id SDZ
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02364077
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84901
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Teva-Escitalopram · DIN 02318180 · $0.3109
Shortage status: resolved shortage (ended 2017-04-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364077
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Escitalopram · DIN 02318180 · 10mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Escitalopram · DIN 02318180
Manufacturer: Teva Canada Limited; listing date 2014-11-27
Health Canada: Marketed since 2014-09-10 · brand TEVA-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Teva canada limited · schedule Prescription
Teva-Escitalopram: Formulary list price $0.3109/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3109 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80368 · Verify on the e-Formulary ↗ (DIN 02318180)
Source record
DIN 02318180: Teva-Escitalopram
Raw flags: sec3=Y
Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.3109; ministry $0.3109
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02318180
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80368
Interchangeable products
Ach-Escitalopram · DIN 02434652 · $0.3109
Apo-Escitalopram · DIN 02295016 · $0.3109
Auro-Escitalopram · DIN 02397358 · $0.3109
Cipralex · DIN 02263238 · $0.3109
Escitalopram · DIN 02429039 · $0.3109
Escitalopram · DIN 02430118 · $0.3109
Jamp Escitalopram · DIN 02508893 · $0.3109
Jamp-Escitalopram · DIN 02429780 · $0.3109
M-Escitalopram · DIN 02471418 · $0.3109
Mar-Escitalopram · DIN 02423480 · $0.3109
Mint-Escitalopram · DIN 02407418 · $0.3109
Mylan-Escitalopram · DIN 02309467 · $0.3109
NRA-Escitalopram · DIN 02476851 · $0.3109
Natco-Escitalopram · DIN 02554909 · $0.3109
PMS-Escitalopram · DIN 02469243 · $0.3109
Ran-Escitalopram · DIN 02385481 · $0.3109
Sandoz Escitalopram · DIN 02364077 · $0.3109
Shortage status: anticipated shortage (last updated 2026-06-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02318180
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Escitalopram ODT · DIN 02454300 · 20mg · Orally Disintegrating Tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Escitalopram ODT · DIN 02454300
Manufacturer: Actavis Pharma Company; listing date 2016-11-30
Health Canada: Marketed since 2020-05-01 · brand ACT ESCITALOPRAM ODT · ATC N06AB10 ESCITALOPRAM · form Tablet (orally-disintegrating) · route Oral · ingredients ESCITALOPRAM 20 MG · company Teva canada limited · schedule Prescription
Act Escitalopram ODT: Formulary list price $1.4052/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.4052 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94082 · Verify on the e-Formulary ↗ (DIN 02454300)
Source record
DIN 02454300: Act Escitalopram ODT
Raw flags: sec3=Y
Item: 281604128; group id 460; item number 1151; lccId None; manufacturer id ACV
Source form: Orally Disintegrating Tablet; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $1.4052; ministry $1.4052
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454300
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94082
Interchangeable products
Cipralex MELTZ · DIN 02391457 · not recorded
Shortage status: resolved shortage (ended 2025-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454300
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Escitalopram · DIN 02434660 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Escitalopram · DIN 02434660
Manufacturer: Accord Healthcare Inc.; listing date 2017-12-21
Health Canada: Marketed since 2016-06-10 · brand ACH-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 20 MG · company Accord healthcare inc · schedule Prescription
Ach-Escitalopram: Formulary list price $0.3310/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3310 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91897 · Verify on the e-Formulary ↗ (DIN 02434660)
Source record
DIN 02434660: Ach-Escitalopram
Raw flags: sec3=Y
Item: 281604119; group id 460; item number 1153; lccId None; manufacturer id ACH
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3310; ministry $0.3310
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02434660
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91897
Interchangeable products
Apo-Escitalopram · DIN 02295024 · $0.3310
Auro-Escitalopram · DIN 02397374 · $0.3310
Cipralex · DIN 02263254 · $0.3310
Escitalopram · DIN 02429047 · $0.3310
Escitalopram · DIN 02430126 · $0.3310
Jamp Escitalopram · DIN 02508907 · $0.3310
Jamp-Escitalopram · DIN 02429799 · $0.3310
M-Escitalopram · DIN 02471426 · $0.3310
Mar-Escitalopram · DIN 02423502 · $0.3310
Mint-Escitalopram · DIN 02407434 · $0.3310
Mylan-Escitalopram · DIN 02309475 · $0.3310
NRA-Escitalopram · DIN 02476878 · $0.3310
Natco-Escitalopram · DIN 02554933 · $0.3310
PMS-Escitalopram · DIN 02469251 · $0.3310
Ran-Escitalopram · DIN 02385503 · $0.3310
Sandoz Escitalopram · DIN 02364085 · $0.3310
Teva-Escitalopram · DIN 02318202 · $0.3310
Shortage status: resolved shortage (ended 2026-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02434660
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Escitalopram · DIN 02295024 · 20mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Escitalopram · DIN 02295024
Manufacturer: Apotex Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-10 · brand APO-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 20 MG · company Apotex inc · schedule Prescription
Apo-Escitalopram: Formulary list price $0.3310/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3310 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78035 · Verify on the e-Formulary ↗ (DIN 02295024)
Source record
DIN 02295024: Apo-Escitalopram
Raw flags: sec3=Y
Item: 281604119; group id 460; item number 1153; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3310; ministry $0.3310
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295024
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78035
Interchangeable products
Ach-Escitalopram · DIN 02434660 · $0.3310
Auro-Escitalopram · DIN 02397374 · $0.3310
Cipralex · DIN 02263254 · $0.3310
Escitalopram · DIN 02429047 · $0.3310
Escitalopram · DIN 02430126 · $0.3310
Jamp Escitalopram · DIN 02508907 · $0.3310
Jamp-Escitalopram · DIN 02429799 · $0.3310
M-Escitalopram · DIN 02471426 · $0.3310
Mar-Escitalopram · DIN 02423502 · $0.3310
Mint-Escitalopram · DIN 02407434 · $0.3310
Mylan-Escitalopram · DIN 02309475 · $0.3310
NRA-Escitalopram · DIN 02476878 · $0.3310
Natco-Escitalopram · DIN 02554933 · $0.3310
PMS-Escitalopram · DIN 02469251 · $0.3310
Ran-Escitalopram · DIN 02385503 · $0.3310
Sandoz Escitalopram · DIN 02364085 · $0.3310
Teva-Escitalopram · DIN 02318202 · $0.3310
Shortage status: resolved shortage (ended 2024-10-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295024
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Escitalopram · DIN 02397374 · 20mg · tablet
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Escitalopram · DIN 02397374
Manufacturer: Auro Pharma Inc.; listing date 2014-12-18
Health Canada: Marketed since 2014-09-10 · brand AURO-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 20 MG · company Auro pharma inc · schedule Prescription
Auro-Escitalopram: Formulary list price $0.3310/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3310 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88233 · Verify on the e-Formulary ↗ (DIN 02397374)
Source record
DIN 02397374: Auro-Escitalopram
Raw flags: sec3=Y
Item: 281604119; group id 460; item number 1153; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3310; ministry $0.3310
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397374
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88233
Interchangeable products
Ach-Escitalopram · DIN 02434660 · $0.3310
Apo-Escitalopram · DIN 02295024 · $0.3310
Cipralex · DIN 02263254 · $0.3310
Escitalopram · DIN 02429047 · $0.3310
Escitalopram · DIN 02430126 · $0.3310
Jamp Escitalopram · DIN 02508907 · $0.3310
Jamp-Escitalopram · DIN 02429799 · $0.3310
M-Escitalopram · DIN 02471426 · $0.3310
Mar-Escitalopram · DIN 02423502 · $0.3310
Mint-Escitalopram · DIN 02407434 · $0.3310
Mylan-Escitalopram · DIN 02309475 · $0.3310
NRA-Escitalopram · DIN 02476878 · $0.3310
Natco-Escitalopram · DIN 02554933 · $0.3310
PMS-Escitalopram · DIN 02469251 · $0.3310
Ran-Escitalopram · DIN 02385503 · $0.3310
Sandoz Escitalopram · DIN 02364085 · $0.3310
Teva-Escitalopram · DIN 02318202 · $0.3310
Shortage status: resolved shortage (ended 2024-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397374
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cipralex · DIN 02263254 · 20mg · tablet
General benefitMarketed · checked 2026-09-18
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Cipralex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Cipralex · DIN 02263254
Manufacturer: Lundbeck Canada Inc.; listing date 2008-11-04
Health Canada: Marketed since 2005-02-14 · brand CIPRALEX -20MG · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 20 MG · company Lundbeck canada inc · schedule Prescription
Ministry pays: $0.3310 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74864 · Verify on the e-Formulary ↗ (DIN 02263254)
Source record
DIN 02263254: Cipralex
Raw flags: sec3=Y
Item: 281604119; group id 460; item number 1153; lccId None; manufacturer id VLH
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $2.5438; ministry $0.3310
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02263254
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74864
Interchangeable products
Ach-Escitalopram · DIN 02434660 · $0.3310
Apo-Escitalopram · DIN 02295024 · $0.3310
Auro-Escitalopram · DIN 02397374 · $0.3310
Escitalopram · DIN 02429047 · $0.3310
Escitalopram · DIN 02430126 · $0.3310
Jamp Escitalopram · DIN 02508907 · $0.3310
Jamp-Escitalopram · DIN 02429799 · $0.3310
M-Escitalopram · DIN 02471426 · $0.3310
Mar-Escitalopram · DIN 02423502 · $0.3310
Mint-Escitalopram · DIN 02407434 · $0.3310
Mylan-Escitalopram · DIN 02309475 · $0.3310
NRA-Escitalopram · DIN 02476878 · $0.3310
Natco-Escitalopram · DIN 02554933 · $0.3310
PMS-Escitalopram · DIN 02469251 · $0.3310
Ran-Escitalopram · DIN 02385503 · $0.3310
Sandoz Escitalopram · DIN 02364085 · $0.3310
Teva-Escitalopram · DIN 02318202 · $0.3310
Shortage status: resolved shortage (ended 2020-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02263254
Shortage record checked 2026-09-13T08:10:21.292534+00:00